SQZ is a clinical-stage biotechnology company developing cell therapies for patients with cancer, infectious diseases and other serious conditions. Co. uses its proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Co. uses Cell Squeeze to create multiple cell therapy platforms focused on directing specific immune responses. Co.'s product candidate, SQZ-PBMC-HPV is in a Phase I clinical trial as for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The SQZ stock yearly return is shown above.
The yearly return on the SQZ stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SQZ annual return calculation with any dividends reinvested as applicable (on ex-dates).
|